COVID JN.1 variant: How timely identification and intervention can help

The rise of the JN.1 variant indicates it might be more infectious or more adept at bypassing our immune defence compared to other variants according to the US Centre of Disease Control (CDC). Health authorities such as the Union Health Ministry of India, World Health Organization (WHO), and the US CDC suggest no significant increase in public health risk from the variant based on available evidence. WHO said current vaccines will continue to protect against severe disease and death from JN.1 variant. The holiday season has increased travel, along with diminishing immunity from previous COVID-19 infections may lead to more people experiencing illness. Even with milder symptoms, the widespread transmission of virus will strain people already dealing with other respiratory illnesses like flu, pneumonia and respiratory syncytial virus (RSV).

There is a need for emphasis on surveillance and precautionary measures in response to the detection of the variant in India, despite the absence of a call for panic. The current vaccines are seen to protect against severe disease and death.

JN.1 variant’s continued growth suggests that the variant is either more transmissible or better at evading our immune systems than other circulating variants. It is too early to know whether or to what extent JN.1 will cause an increase in infections or hospitalizations.

It’s important to know that existing vaccines, tests, and treatments still work well against JN.1, so this variant does not affect the US CDC’s recommendations.

Are the COVID-19 vaccine and treatments effective against JN.1?
The CDC notes that the spike protein is part of the virus that vaccines target and, as a result, the COVID-19 vaccine should work against JN.1 variant; they expect this variant will be similar.

If you get COVID-19, contact your doctor for an antiviral medication. the key thing is to make sure that high-risk individuals are protected with updated vaccines and are quickly prescribed an antiviral if they become infected. If diagnosed in time treatment can decrease the likelihood of severity of disease. Treatment protocols for JN.1 variant will align with existing COVID-19 management strategies, including antiviral medications, supportive care, and oxygen therapy for severe cases. Ongoing research will inform specific treatment guidelines tailored to this variant.

Steps to protect yourself against JN.1 and other circulating variants
1. The spread of JN.1 does not alter the US CDC’s COVID-19 recommendations. COVID-19 remains a serious public health threat, especially for people at higher risk of severe disease, such as older adults, infants, and people with certain disabilities and underlying health conditions. We encourage you to take steps to protect yourself and others.


2. These actions can help protect you and your loved ones against the most severe effects of COVID-19

3. Get your updated COVID-19 vaccine.

4. Test if you develop respiratory symptoms or are exposed to someone who has COVID-19.

5. Talk to a healthcare provider about treatment if you test positive and are at higher risk for severe effects of COVID-19.

Following COVID-appropriate measures like washing hands with soap and water, social distancing, masking, and avoiding crowds must be followed in all sincerity in order to protect spread of Coronavirus. In conclusion, staying informed, practising preventive measures, and seeking prompt medical attention are crucial in mitigating its impact.

(Author: Dr. Apurrva Sawant: Preventive Healthcare Expert and Founder of Careport Private Limited)